plerixafor has been researched along with Ventricular Dysfunction, Left in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calderone, A; Clement, R; El-Helou, V; Gillis, MA; Gosselin, H; Proulx, C; Villeneuve, L | 1 |
1 other study(ies) available for plerixafor and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction.
Topics: Animals; Benzylamines; Chemokine CXCL12; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; RNA, Messenger; Ventricular Dysfunction, Left; Ventricular Remodeling | 2007 |